We initially considered that LN infiltration by CD1a-DCs would be associated with favorable clinical outcomes and that if CD1a-DCs migrated into regional LNs from the primary site, there would be CD1a-DCs in not only metastatic LNs but also in LNs without cancer metastasis. This evidence concerns the gene CD1A and cancer.